Contrasting effects of captopril and nifedipine in normotensive patients with incipient diabetic nephropathy. 1988

A Mimran, and A Insua, and J Ribstein, and L Monnier, and J Bringer, and J Mirouze
Department of Medicine, Hôpital Lapeyronie, Centre Hospitalier Universitaire, Montpellier, France.

Microalbuminuria is a reliable predictor of the eventual development of overt diabetic nephropathy and blood pressure is known to accelerate the course of this nephropathy. In the present studies, the effect of a 6-week treatment by placebo (n = 7), nifedipine (n = 7) and captopril (n = 8) on renal function and urinary excretion of albumin (UAE) was investigated in normotensive, insulin-dependent, diabetic patients with incipient nephropathy (UAE greater than 15 micrograms/min). No change in arterial pressure, renal function or UAE was observed in the placebo group. In response to captopril and nifedipine, mean arterial pressure decreased slightly and similarly in both groups. Glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) increased to a similar extent in the nifedipine group, thus resulting in no change in filtration fraction (FF). In response to captopril, GFR was unchanged whilst ERPF increased; as a consequence FF decreased. Opposite changes in UAE were observed in response to the two treatments; UAE decreased by 40% in the captopril group and by 40% in nifedipine-treated patients. These results indicate that intrarenal changes may be crucial with respect to the effect of therapy on UAE. It is suggested that only agents which reduce FF and probably intraglomerular capillary pressure, such as converting enzyme inhibitors, alter UAE and may possibly interfere with the course of incipient diabetic nephropathy in normotensive patients.

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009543 Nifedipine A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure. Adalat,BAY-a-1040,Bay-1040,Cordipin,Cordipine,Corinfar,Fenigidin,Korinfar,Nifangin,Nifedipine Monohydrochloride,Nifedipine-GTIS,Procardia,Procardia XL,Vascard,BAY a 1040,BAYa1040,Bay 1040,Bay1040,Monohydrochloride, Nifedipine,Nifedipine GTIS
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D002216 Captopril A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin. (S)-1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline,Capoten,Lopirin,SQ-14,225,SQ-14,534,SQ-14225,SQ-14534,SQ 14,225,SQ 14,534,SQ 14225,SQ 14534,SQ14,225,SQ14,534,SQ14225,SQ14534
D003928 Diabetic Nephropathies KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE. Diabetic Glomerulosclerosis,Glomerulosclerosis, Diabetic,Diabetic Kidney Disease,Diabetic Nephropathy,Intracapillary Glomerulosclerosis,Kimmelstiel-Wilson Disease,Kimmelstiel-Wilson Syndrome,Nodular Glomerulosclerosis,Diabetic Kidney Diseases,Glomerulosclerosis, Nodular,Kidney Disease, Diabetic,Kidney Diseases, Diabetic,Kimmelstiel Wilson Disease,Kimmelstiel Wilson Syndrome,Nephropathies, Diabetic,Nephropathy, Diabetic,Syndrome, Kimmelstiel-Wilson
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

A Mimran, and A Insua, and J Ribstein, and L Monnier, and J Bringer, and J Mirouze
January 1982, Journal of cardiovascular pharmacology,
A Mimran, and A Insua, and J Ribstein, and L Monnier, and J Bringer, and J Mirouze
December 1992, American journal of kidney diseases : the official journal of the National Kidney Foundation,
A Mimran, and A Insua, and J Ribstein, and L Monnier, and J Bringer, and J Mirouze
November 1990, Diabetes,
A Mimran, and A Insua, and J Ribstein, and L Monnier, and J Bringer, and J Mirouze
August 1993, Journal of human hypertension,
A Mimran, and A Insua, and J Ribstein, and L Monnier, and J Bringer, and J Mirouze
October 1996, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
A Mimran, and A Insua, and J Ribstein, and L Monnier, and J Bringer, and J Mirouze
July 1991, BMJ (Clinical research ed.),
A Mimran, and A Insua, and J Ribstein, and L Monnier, and J Bringer, and J Mirouze
January 1985, Journal of cardiovascular pharmacology,
A Mimran, and A Insua, and J Ribstein, and L Monnier, and J Bringer, and J Mirouze
January 1991, BMJ (Clinical research ed.),
A Mimran, and A Insua, and J Ribstein, and L Monnier, and J Bringer, and J Mirouze
March 1990, Journal of hypertension. Supplement : official journal of the International Society of Hypertension,
A Mimran, and A Insua, and J Ribstein, and L Monnier, and J Bringer, and J Mirouze
January 1995, Nihon Jinzo Gakkai shi,
Copied contents to your clipboard!